Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

AIMS: Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Kausik K, Kallend, David, Leiter, Lawrence A, Raal, Frederick J, Koenig, Wolfgang, Jaros, Mark J, Schwartz, Gregory G, Landmesser, Ulf, Garcia Conde, Lorena, Wright, R Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769955/
https://www.ncbi.nlm.nih.gov/pubmed/36331315
http://dx.doi.org/10.1093/eurheartj/ehac615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769955/
https://www.ncbi.nlm.nih.gov/pubmed/36331315
http://dx.doi.org/10.1093/eurheartj/ehac615

Ejemplares similares